-transparent.png){kind=logo}
A comparative study of the effects of cholestyramine and neomycin has been carried out in 35 patients with severe type II hyperlipoproteinaemia. Both agents were administered during a period of 18 weeks, the daily dosages being 12, 16 or 20 g cholestyramine and 1, 1.5 or 2 g neomycin. The mean decrease in cholesterol concentration was 22% with cholestyramine and 23% with neomycin. There was no difference in effect between the two agents and between the doses used. No significant influence on triglyceride concentration and on body weight was observed. No signs of deficiencies in fat-soluble vitamins were found. Anticoagulant requirements increased during cholestyramine medication. No signs of hyperchloraemic acidosis were observed during treatment with colestyramine. Cholestyramine was tolerated less well than neomycin: it had to be discontinued in 8 cases. Neomycin was not tolerated by 3 patients. The majority of the patients preferred neomycin.
R W Schade, and
A van't Laar, and
C L Majoor, and
A P Jansen
January 1982,
Artery,
R W Schade, and
A van't Laar, and
C L Majoor, and
A P Jansen
June 1981,
Lancet (London, England),
R W Schade, and
A van't Laar, and
C L Majoor, and
A P Jansen
December 1973,
Casopis lekaru ceskych,
R W Schade, and
A van't Laar, and
C L Majoor, and
A P Jansen
January 1978,
Atherosclerosis,
R W Schade, and
A van't Laar, and
C L Majoor, and
A P Jansen
June 1977,
British journal of clinical pharmacology,
R W Schade, and
A van't Laar, and
C L Majoor, and
A P Jansen
May 1985,
The American journal of cardiology,
R W Schade, and
A van't Laar, and
C L Majoor, and
A P Jansen
November 1972,
JAMA,
R W Schade, and
A van't Laar, and
C L Majoor, and
A P Jansen
January 1973,
Acta medica Scandinavica,
R W Schade, and
A van't Laar, and
C L Majoor, and
A P Jansen
March 1973,
Clinics in endocrinology and metabolism,
R W Schade, and
A van't Laar, and
C L Majoor, and
A P Jansen
February 1990,
European heart journal,
